Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 940-265-8 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2004-10-04 to 2005-01-18
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP compliant guideline study (OECD 407 adopted 1996) with acceptable deviations from OECD guideline 407 adopted 2008: less organs were weighed and microscopically examined.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 004
- Report date:
- 2005
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.7 (Repeated Dose (28 Days) Toxicity (Oral))
- Version / remarks:
- September 30, 1996
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Version / remarks:
- July 27, 1995
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: Japanese Guidelines for Screening, Toxicity Testing of Chemicals : Testing Methods for new Substances, enacted July 13, 1974, amended December 5, 1986
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Details on test material:
- - Description: Red solid
- Storage conditions: at room temperature (20 +/- 5 °C) in the original container, away from direct sunlight
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: RCC Ltd.; Laboratory Animal Services; CH-4414 Füllinsdorf / Switzerland
- Age at study initiation: 6 weeks;
- Weight at study initiation: Males: 140.0 - 163.3 grams (mean 153.9 grams; Females: 117.0-137.8 grams (mean 124.1 grams);
- Fasting period before study: No
- Housing: In groups of five in Makrolon type-4 cages with wire mesh tops and standardized softwood bedding ('Lignocel' Schill AG, CH-4132 Muttenz/Switzerland)
- Diet: Pelleted standard Provimi Kliba 3433 (batch no. 53/04 and 63/04) rat maintenance diet (Provimi Kliba AG, CH-4303 Kaiseraugst/ Switzerland) ad libitum;
- Water: Community tap-water from Itingen was available ad libitum in water bottles
- Acclimation period: 7 days;
ENVIRONMENTAL CONDITIONS
- Temperature: 22 +/- 3 °C;
- Humidity: relative humidity range: 30-70 %;
- Air changes: 10-15 air changes per hour;
- Photoperiod: 12-hour fluorescent light/12-hour dark cycle with music during the light period.
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- polyethylene glycol
- Remarks:
- PEG 300
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
The test item was weighed into a glass beaker on a tared Mettler balance and the vehicle added (weight/volume). The mixtures were prepared using a magnetic stirrer and stored at room temperature (15-25°C).
Homogeneity of the test item in the vehicle was maintained during the daily administration period using a magnetic stirrer.
VEHICLE
- Justification for use and choice of vehicle: solubilty of the test item;
- Amount of vehicle (if gavage): 5 mL/ kg body weight; - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Concentration, homogeneity and stability (after 2 hours and 7 days) of the dose formulations were determined in samples taken on the day of animal delivery. Concentration and homogeneity of the dose formulations were determined in samples taken during week 3 of the treatment. The analyses were performed according to a HPLC method.
The results demontrated that the nominal concentrations wer achieved, that the test item was homogeneously distributed in the vehicle and stable in the vehicle under storage conditions for two hours and for seven days. - Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- daily
Doses / concentrations
- Remarks:
- Doses / Concentrations:
Group 1: 0 mg/kg body weight; Group 2: 50 mg/kg body weight; Group 3: 200 mg/kg body weight; Group 4: 1000 mg/kg body weight
Basis:
actual ingested
- No. of animals per sex per dose:
- 5 animals per sex per dose in treatment groups; 5 animals per sex per dose in the recovery groups (0 and 1000 mg/kg bw)
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Based on results of a non-GLP 5-day dose range-finding study
- Post-exposure recovery period in satellite groups: 14 days
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: The animals were observed for clinical signs once before commencement of administration; twice daily on days 1-3; as well as once daily on days 4-28 and once daily during days 29-42 (recovery).
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: The animals were observed in their home cages, outside their home cages in a standard arena and in the hand. These observations were performed in random sequence once before commencement of administration and once weekly (weeks 1-3) thereafter.
BODY WEIGHT: Yes
- Time schedule for examinations: Body weights were recorded weekly during pretest, treatment and recovery and before necropsy.
FOOD CONSUMPTION AND COMPOUND INTAKE: The food consumption was recorded once during the pretest period and weekly thereafter.
WATER CONSUMPTION: No
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: after 4 weeks and after 6 weeks (recovery)
- Anaesthetic used for blood collection: yes (isoflurane)
- Animals fasted: Yes
- How many animals: All
- Parameters checked/examined: Erythrocyte count, Hemoglobin, Hematocrit, Mean corpuscular volume, Red cell volume distribution width, Mean corpuscular hemoglobin, Mean corpuscular hemoglobin concentration, Hemoglobin concentration distribution width, Platelet (thrombocyte) countReticulocyte count, Reticulocyte maturity index, Methemoglobin, Total leukocyte count, Differential leukocyte count, Coagulation:, Thromboplastin time, Activated partial thromboplastin time
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: after 4 weeks and after 6 weeks (recovery)
- Anaesthetic used for blood collection: yes (isoflurane)
- Animals fasted: Yes
- How many animals: All
- Parameters checked/examined: Glucose, Urea, Creatinine, Bilirubin, total, Cholesterol, total, Triglycerides, Phospholipids, Aspartate aminotransferase, Alanine aminotransferase, Lactate dehydrogenase, Glutamate dehydrogenase, Creatine kinase, Alkaline phosphatase, Gamma-glutamyl-transferas, Sodium, Potassium, Chloride, Calcium, Phosphorus inorganic, Protein, total, Albumin, Globulin, Albumin/Globulin ratio
URINALYSIS: Yes
- Time schedule for collection of urine: during the 18-hour fasting period
- Metabolismus cages used for collection of urine: Yes
- Animals fasted: Yes
- Parameters checked/were examined: Volume (18 hours), Specific gravity (relative density), Color, Appearance, pH, Nitrite, Protein, Glucose, Ketones, Urobilinogen, Bilirubin, Erythrocytes, Leukocytes
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: During week 4;
- Dose groups that were examined: all dose groups;
- Battery of functions tested: sensory activity / grip strength / motor activity - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
All animals were weighed and necropsied. Descriptions of all macroscopic abnormalities were recorded.
Samples of the following tissues and organs were collected from all animals at necropsy and fixed in neutral phosphate buffered 4 % formaldehyde solution (unless otherwise indicated):
Adrenal glands (weighed), Aorta, Bone (sternum, femur including joint), Bone marrow (femur), Brain (4 levels)(weighed), Cecum, Colon, Duodenum, Epididymides (fixed in Bouin's solution)(weighed), Esophagus, Eyes with optic nerve (fixed in Davidson's solution), Harderian gland (fixed in Davidson's solution), Heart(weighed), Ileum, with Peyer's patches, Jejunum with Peyer's patches, Kidneys(weighed), Larynx, Lacrimal gland (exorbital), Liver(weighed), Lungs (infused with formalin at necropsy), Lymph nodes (mesenteric, mandibular), Mammary gland area, Nasal cavity, Ovaries(weighed), Pancrea, Pituitary gland, Prostate gland, Rectum, Salivary glands (mandibular, sublingual), Sciatic nerve, Seminal vesicles, Skeletal muscle, Skin, Spinal cord (cervical, midthoracic, lumbar), Spleen(weighed), Stomach, Testes (fixed in Bouin's solution)(weighed), Thymus(weighed), Thyroid (incl. parathyroid gland, if possible), Tongue, Trachea, Urinary bladder (infused with formalin at necropsy), Uterus, Vagina,Gross lesions
The following organ weights were recorded on the scheduled dates of necropsy:
Brain, Heart, Liver, Thymus, Kidneys, Adrenals, Spleen, Testes, Epididymides, Ovaries
HISTOPATHOLOGY: Yes
- Slides of all organs and tissues listed were collected at scheduled sacrifice from the animals of control and high-dose groups and were examined by a pathologist: Adrenal glands, Bone marrow (femur), Brain (4 levels), Cecum, Colon, Duodenum, Epididymides (fixed in Bouin's solution), Heart, Ileum, with Peyer's patches, Jejunum with Peyer's patches, Kidneys, Liver, Lungs (infused with formalin at necropsy), Lymph nodes (mesenteric, mandibular), Ovaries, Prostate gland, Rectum, Sciatic nerve, Seminal vesicles, Spinal cord (cervical, midthoracic, lumbar), Spleen, Stomach, Testes (fixed in Bouin's solution), Thymus, Thyroid (incl. parathyroid gland, if possible), Trachea, Urinary bladder (infused with formalin at necropsy), Uterus, Vagina, Gross lesions - Other examinations:
- NA
- Statistics:
- The following statistical methods were used to analyze the grip strength, locomotor activity, body weight, organ weights and ratios, as well as:
• The Dunnett-test (many to one t-test) based on a pooled variance estimate were applied if the variables could be assumed to follow a normal distribution for the comparison of the treated groups and the control groups for each sex.
• Fisher's exact-test were applied to the macroscopic findings.
The following statistical methods were used for statistical analysis of clinical laboratory data:
• Quantitative data were analyzed by a one-way analysis of variance (ANOVA) when the variances are considered homogeneous according to Bartlett. Alternatively, if the variances are considered to be heterogenous (p<0.05), a non-parametric Kruskal-Wallis test was used. Treated groups were compared to the control groups using Dunnett's test if the ANOVA was significant at the 5% level and by Dunn's test in the case of a significant Kruskal-Wallis test (p<0.05).
Results and discussion
Results of examinations
- Details on results:
- CLINICAL SIGNS AND MORTALITY
All animals survived until their respective scheduled necropsy.
BODY WEIGHT AND WEIGHT GAIN
The mean body weights and the mean body weight gain of the test item-treated rats compared favorably with those of the respective controls.
FOOD CONSUMPTION
The mean daily food consumption values of the test item-treated rats were unaffected during the treatment and recovery periods when compared with the control rats.
HAEMATOLOGY
No test item-related differences of toxicological relevance were noted in the hematology parameters after treatment or recovery.
CLINICAL CHEMISTRY
No test item-related differences of toxicological relevance were noted in the clinical biochemistry parameters after treatment or recovery.
URINALYSIS
No test item-related differences of toxicological relevance were noted in the urine parameters after treatment or recovery.
NEUROBEHAVIOUR
No test item-related findings of toxicological relevance were noted during functional observational battery (week 4) at any dose level.
ORGAN WEIGHTS
No test item-related differences of toxicological relevance were noted in the mean absolute or relative organ weights at any dose level tested.
All differences in the mean absolute or relative organ weights noted after recovery were considered to be incidental and unrelated to the test item administration.
MACROSCOPIC / MICROSCOPIC FINDINGS
At necropsy, no test item-related macroscopic findings were recorded.
Microscopically, no test item-related histopathological findings were recorded.
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Although ECHA is providing a lot of online material in your language, part of this page is only in English. More about ECHA’s multilingual practice.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
the-echa-website-uses-cookies
find-out-more-on how-we-use-cookies